EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE
https://doi.org/10.17650/2073-8803-2016-11-4-54-60
Abstract
Among drug-resistant epilepsies, epileptic syndromes, characterized by combination of several types of seizures, are considered to be the most difficult in terms of treatment. Lennox–Gastaut syndrome is one of them. It manifests with polymorphic seizures (tonic axial, myatonic, atypical absence seizures, status epilepticus of minor motor seizures, myoclonic, generalized convulsive, and focal seizures). This is a heterogeneous disease, represented by a complex of clinical and electroencephalographic manifestations with various etiology. Current review is devoted to a novel antiepileptic drug rufinamide, which has a new mechanism of action. The drug has been registered in Russia in 2015. The authors also describe their own experience of rufinamide usage in the treatment of drug-resistant focal epilepsy as a part of multicomponent therapy for polymorphic seizures. One patient achieved clinical remission for 16 months; the second one had more than 50 % decrease in seizures frequency with a remission of drop-attacks.
About the Authors
I. O. Shchederkina
Morozov Children’s City Clinical Hospital, Moscow Healthcare Department;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1/9 4th Dobryninskiy Pereulok, Moscow 119049;
1 Ostrovityanova St., Moscow, 117997
K. A. Orlova
Morozov Children’s City Clinical Hospital, Moscow Healthcare Department;
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1/9 4th Dobryninskiy Pereulok, Moscow 119049;
1 Ostrovityanova St., Moscow, 117997
I. E. Koltunov
Morozov Children’s City Clinical Hospital, Moscow Healthcare Department;
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
1/9 4th Dobryninskiy Pereulok, Moscow 119049;
6 Miklukho-Maklaya St., Moscow 117198
M. Yu. Dorofeeva
Acad. Yu.E. Vel’tishchev Research Clinical Institute of Pediatrics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
2 Taldomskaya St., Moscow 125412
Russian Federation
2 Taldomskaya St., Moscow 125412
References
1. Инструкция по медицинскому применению препарата Иновелон (руфинамид) ЛП-002841. [Guidelines for medical use of Inovelon (rufinamide) LP-002841. (In Russ.)].
2. Карлов В.А., Мухин К.Ю., Гузева В.И. Современные подходы к критериям выбора фармакотерапии эпилепсии в детском возрасте. Русский журнал детской неврологии 2013;8(4)–2014;9(1):61–2. [Karlov V.A., Mukhin K.Yu., Guzeva V.I. Modern approaches to drug selection in the therapy of epilepsy in children. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2013;8(4)–2014;9(1):61–2. (In Russ.)].
3. Мазин П.В., Шешунов И.В., Кислицын Ю.В., Мазина Н.К. Эффективность и безопасность лечения эпилепсии руфинамидом (по данным метаанализа). Журнал неврологии и психиатрии им. С.С. Корсакова 2016;8:40–3. [Mazin P.V., Sheshunov I.V., Kislitsyn Yu.V., Mazina N.K. Effectiveness and safety of rufinamide in the treatment of epilepsy (according to the data of meta-analysis). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2016;8:40–3. (In Russ.)].
4. Федеральное руководство по детской неврологии. Подред. В.И. Гузевой. М.: МК, 2016. 656 c. [Federal child neurology guidelines. Ed. by V.I. Guzeva. Moscow: MK, 2016. 656 p. (In Russ.)].
5. Al-Banji M.H., Zanr D.K., Jan M.M. Lennox–Gastaut syndrome. Manag Upd Neurosci (Riyadh) 2015;20(3):207–12.
6. Albini M., Morano A., Fanella M. et al. Effectiveness of rufinamide in treatment of idiopathic generalized epilepsy with atypical evolution: case report and rewiev of the literature. Clon EEG Neurosci 2016;47(2):162–6.
7. Arzimanoglou A., French J., Blume W.T. Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009;8:82–93.
8. Beaumanoir A., Dravet Ch. The Lennox–Gastaut syndrome. In: Epileptic symdromes in infancy, childhood and adolescence. 2th edn. Ed. by. J. Roger, M. Bureau, Ch. Dravet et al. London: John Libbey, 1992. Pp. 307–12.
9. Coppola G., Besag F., Cusmai R. et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol 2014;18(6):685–90.
10. Glauser T., Kluger G., Sachdeo R. et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008:70(21):641–5.
11. Guerrini R., Marini C. Epileptic encephalopathies. In: Epilepsy and epileptic seizures. Ed. by S. Shor-von, R. Guerrini, M. Cook, S. Lhatoo. UK: Oxford University Press, 2013. Pp. 177–80.
12. Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res 2012;2(2):33–7.
13. Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, openlabel extension study. Acta Neurol Scand 2010;122:202–8.
14. Kwan P., Broudie M.J. Effectiveness of first antiepiltptic drug. Epilepsia 2001;42(10):1255–60.
15. Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008;70(1):54–65.
16. Shorvon S. The epidemiology of epilepsy. In: Lecture notes. British brabch of International League against epilepsy. Ed. by J.S. Duncan, J.Q. Gill. Oxford: Keble College, 1995. Pp. 1–6.
17. Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox–Gastaut syndrome: a comprehensive overview. Paediatric Drugs 2011;13(2):97–106.
Review
For citations:
Shchederkina I.O., Orlova K.A., Koltunov I.E., Dorofeeva M.Yu. EFFICACY OF RUFINAMIDE IN THE TREATMENT OF DRUG-RESISTANT FOCAL EPILEPSIES IN PAEDIATRIC PRACTICE. Russian Journal of Child Neurology. 2016;11(4):54-60. (In Russ.) https://doi.org/10.17650/2073-8803-2016-11-4-54-60
Views:
700
Email this article 